Key result
Tirofiban combined with heparin significantly improved NIHSS, Barthel index, and 90-day Modified Rankin Scale compared to aspirin plus clopidogrel in mild to moderate acute ischemic stroke (P<0.05).
Why the study?
Although tirofiban can be used for acute ischemic stroke, this study evaluated the efficacy and safety of tirofiban combined with heparin in mild to moderate AIS.
Does tirofiban combined with heparin improve neurological function and long-term prognosis in patients with mild to moderate acute ischemic stroke?
RCT (n=98)
randomly divided
Does tirofiban combined with heparin improve neurological function and long-term prognosis in patients with mild to moderate acute ischemic stroke?
Tirofiban combined with heparin for 48 hours followed by dual antiplatelet therapy improves neurological function and 90-day prognosis in mild to moderate acute ischemic stroke without increasing adverse reactions.
Tirofiban can be used to treat patients with acute ischemic stroke (AIS), this study was to evaluate the efficacy and safety of tirofiban combined with heparin in the treatment of mild to moderate AIS. A total of 98 patients with mild to moderate AIS randomly were divided into 2 groups within 48 h: the treatment group treated with tirofiban and, and the control group treated with aspirin + clopidogrel. The treatment group was given the same scheme as the control group after the treatment of tirofiban combined with heparin for 48 h. It was found that, compared with the control group, a significant decreased National Institute of Health stroke scale (NIHSS) was found in 48 h and 14 d, especially to the Barthel index (BI) in the treatment group (P < 0.05). Furthermore, Modified Rankin Scale (MRS, ≤2) in the treatment group was significantly upregulated in 90 d (P < 0.05). However, there were no significant differences in the adverse drug reactions between the two groups. It was indicated that nerve function and long-term prognosis in patients undergoing heparin for mild to moderate AIS were obviously improved than the control group.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2020) conducted an RCT in mild to moderate acute ischemic stroke (n=98). Tirofiban combined with heparin vs. Aspirin + clopidogrel was evaluated on National Institute of Health stroke scale (NIHSS) at 48 h and 14 d (p=<0.05). Tirofiban combined with heparin significantly improved NIHSS, Barthel index, and 90-day Modified Rankin Scale compared to aspirin plus clopidogrel in mild to moderate acute ischemic stroke (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: